Valuation: Recursion Pharmaceuticals, Inc.

Market Cap 2.41B 2.16B 1.98B 1.8B 3.36B 229B 3.42B 23.67B 9.5B 120B 9.04B 8.85B 379B P/E 2026 *
-4.55x
P/E 2027 * -4.64x
Enterprise Value 1.96B 1.75B 1.61B 1.46B 2.73B 186B 2.78B 19.21B 7.71B 97.69B 7.34B 7.18B 308B EV / Sales 2026 *
46.8x
EV / Sales 2027 * 38.7x
Free-Float
98.17%
Yield 2026 *
-
Yield 2027 * -
1 day-1.86%
1 week+5.39%
Current month-0.62%
1 month-2.79%
3 months+25.94%
6 months+13.78%
Current year-2.08%
1 week 3.73
Extreme 3.7301
4.52
1 month 3.44
Extreme 3.44
5.19
Current year 2.77
Extreme 2.77
5.24
1 year 2.77
Extreme 2.77
5.76
3 years 2.77
Extreme 2.77
15.74
5 years 2.77
Extreme 2.77
21.19
10 years 2.77
Extreme 2.77
42.81
Manager TitleAgeSince
Chief Executive Officer 43 01/01/2026
Director of Finance/CFO 48 20/11/2024
Chief Tech/Sci/R&D Officer 57 06/04/2026
Director TitleAgeSince
Director/Board Member 44 04/11/2013
Director/Board Member 62 04/11/2013
Director/Board Member 37 01/09/2016
Date Insider Type Main position Quantity % Market Cap. Importance
06/10/26 Sell

Founder

-50,000 0.0093%
06/10/26 Exercice

Director

75,000 0.0140%
01/10/26 Free

Director

4,607 0.0009%
Change 5-day change 1-year change 3-year change Capi.($)
-2.11%+5.39%-26.38%-23.42% 2.41B
-2.37%-4.19%+39.49%+63.21% 63.77B
-3.07%+0.33%+10.28%+68.93% 56.37B
+0.70%+2.05%+20.14%+102.44% 54.62B
-2.13%-4.16%+22.61%+37.68% 44.06B
-2.26%-1.82%+16.76%+100.01% 42.11B
-1.68%+2.78%+218.57%+793.66% 41B
-5.47%+24.76%+98.34%+87.34% 34.92B
+0.21%-1.23%+14.81%+47.35% 32.82B
-2.53%+17.84%-40.94%+339.74% 24.7B
Average -2.02%+7.85%+37.37%+161.69% 39.68B
Weighted average by Cap. -1.98%+5.66%+44.63%+163.49%

Financials

2026 *2027 *
Net sales 41.78M 37.42M 34.42M 31.19M 58.3M 3.97B 59.39M 410M 165M 2.09B 157M 153M 6.58B 53.03M 47.49M 43.68M 39.58M 73.99M 5.03B 75.37M 521M 209M 2.65B 199M 195M 8.35B
Net income -466M -418M -384M -348M -651M -44.29B -663M -4.58B -1.84B -23.3B -1.75B -1.71B -73.47B -506M -453M -417M -377M -705M -48.01B -719M -4.97B -1.99B -25.25B -1.9B -1.86B -79.64B
Net Debt -453M -406M -373M -338M -632M -43.04B -644M -4.45B -1.79B -22.64B -1.7B -1.66B -71.4B -359M -322M -296M -268M -501M -34.1B -510M -3.53B -1.42B -17.94B -1.35B -1.32B -56.57B
Projected Income Statement - Annual - Recursion Pharmaceuticals, Inc.
Logo Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
Employees
600
Date Price Change Volume
02/11/26 $3.985 -1.12% 7,272,929
30/10/26 $4.030 -4.95% 24,414,759
29/10/26 $4.240 -2.53% 20,964,654
28/10/26 $4.350 +7.41% 28,496,864
27/10/26 $4.050 +6.58% 22,169,969
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Recursion Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
4.030USD
Average target price
7.317USD
Spread / Average Target
+81.56%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Recursion Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. RXRX Stock